The blood concentration of the antibiotic colistin is determined in patients in whom kidney function is reduced such that a renal replacement therapy is needed. Hypothesis:no dose reduction is needed in patients undergoing continuous renal replacement therapy over 24h because colistin is sufficiently removed by this procedure.
After administration of intravenous Colistin multiple blood samples are drawn over one dosing interval on day 1, 3, and 5 of treatment. Patients are monitored for signs of neuro- and nephrotoxicity
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Colistin i.v. three times daily as long a necessary for infection treatment
University Hospital of Zurich, Dept. of Pharmacology and Toxicology
Zurich, Canton of Zurich, Switzerland
RECRUITINGArea under the curve (AUC)
Time frame: predose, and 0.5, 1, 2, 4, 6, 8 hours after administration
Sings of neurotoxicity and nephrotoxicity
Clinical investigation daily by assessing clinical signs and questioning the patient regarding sign of neuropathy and difficulty breathing in non intubated patients. Questioning the treating physician in intubated patients regarding objective signs of increased ventilation support.
Time frame: Expected average of follow up is about 14 days.
Sings of neurotoxicity and nephrotoxicity
Clinical investigation daily by assessing clinical signs and questioning the patient regarding sign of neuropathy and difficulty breathing in non intubated patients. Questioning the treating physician in intubated patients regarding objective signs of increased ventilation support. The patients will be followed for the duration of colistin administration at the dose studied.
Time frame: Expected average of follow up is about 14 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.